Julius A. Vida
Nessuna posizione attualmente
Profilo
Julius A.
Vida is the founder of Vida International Pharmaceutical Consultants, which was founded in 1993.
He held the title of President from 1993 to 2018.
Dr. Vida's former jobs include Director positions at Medarex, Inc. from 1994 to 2009, Orphan Medical, Inc., Spectrum Pharmaceuticals, Inc. as Lead Director, YM BioSciences, Inc., FibroGen, Inc., Almac Sciences (Scotland) Ltd., Almac Group Ltd., and OsteoScreen, Inc. He also held the title of VP-Business Development & Strategic Planning at Bristol Myers Squibb Co. from 1975 to 1993.
Dr. Vida's education history includes a graduate and doctorate degree from Carnegie Mellon University, an MBA from The Trustees of Columbia University in The City of New York, and an undergraduate degree from Eotvos Lorand University.
Precedenti posizioni note di Julius A. Vida
| Società | Posizione | Fine |
|---|---|---|
| Vida International Pharmaceutical Consultants | Fondatore | 10/06/2018 |
| OsteoScreen, Inc. | Direttore/Membro del Consiglio | 10/06/2018 |
Almac Sciences (Scotland) Ltd.
 Almac Sciences (Scotland) Ltd. Chemicals: SpecialtyProcess Industries Part of Chemical Synthesis Services Business, Almac Sciences (Scotland) Ltd. is a British company that produces custom peptides and proteins. The company is based in Penicuik, UK. | Direttore/Membro del Consiglio | 10/06/2018 |
Medarex, Inc.
 Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Direttore/Membro del Consiglio | 27/08/2009 |
YM BioSciences, Inc.
 YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Direttore/Membro del Consiglio | 28/11/2007 |
Formazione di Julius A. Vida
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Carnegie Mellon University | Doctorate Degree |
| Eotvos Lorand University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SPECTRUM PHARMACEUTICALS, INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Aziende private | 7 |
|---|---|
Medarex, Inc.
Medarex, Inc. Miscellaneous Commercial ServicesCommercial Services Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey. | Commercial Services |
Orphan Medical, Inc.
 Orphan Medical, Inc. Pharmaceuticals: MajorHealth Technology Orphan Medical, Inc. develops and markets pharmaceutical and health care products. The company was founded in 1993 and is located in Minnetonka, MN. | Health Technology |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Almac Group Ltd.
 Almac Group Ltd. Pharmaceuticals: MajorHealth Technology Almac Group Ltd. manufactures and distributes pharmaceutical products. The firm’s services include diagnostics, API services and chemical development, pharmaceutical development, analytical and solid state services, clinical services, clinical technologies and commercial services. The company was founded by Allen McClay in 2002 and is headquartered in Craigavon, the United Kingdom. | Health Technology |
| Vida International Pharmaceutical Consultants | |
| OsteoScreen, Inc. | |
Almac Sciences (Scotland) Ltd.
Almac Sciences (Scotland) Ltd. Chemicals: SpecialtyProcess Industries Part of Chemical Synthesis Services Business, Almac Sciences (Scotland) Ltd. is a British company that produces custom peptides and proteins. The company is based in Penicuik, UK. | Process Industries |
- Borsa valori
- Insiders
- Julius A. Vida
